A detailed history of Gilder Gagnon Howe & CO LLC transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Gilder Gagnon Howe & CO LLC holds 11,349 shares of JANX stock, worth $544,752. This represents 0.01% of its overall portfolio holdings.

Number of Shares
11,349
Previous 11,554 1.77%
Holding current value
$544,752
Previous $483,000 6.63%
% of portfolio
0.01%
Previous 0.01%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$35.29 - $50.26 $7,234 - $10,303
-205 Reduced 1.77%
11,349 $515,000
Q2 2024

Aug 14, 2024

SELL
$35.12 - $64.78 $1,299 - $2,396
-37 Reduced 0.32%
11,554 $483,000
Q1 2024

May 15, 2024

BUY
$7.93 - $49.75 $91,916 - $576,652
11,591 New
11,591 $436,000

Others Institutions Holding JANX

About Janux Therapeutics, Inc.


  • Ticker JANX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,663,000
  • Market Cap $2B
  • Description
  • Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...
More about JANX
Track This Portfolio

Track Gilder Gagnon Howe & CO LLC Portfolio

Follow Gilder Gagnon Howe & CO LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gilder Gagnon Howe & CO LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gilder Gagnon Howe & CO LLC with notifications on news.